Ritter Pharmaceuticals Inc (RTTR)

[ash111]

RTTR updated DD(all in one):

Current market cap of about $15m(7,792,433 O/S) is very low so if we get good news here(data,NDS submission,a partnership,a buyout this could bring a lot of value to shareholders,imo.

Nov 18, 2015 updates(news):
Recent Highlights

1. Closed initial public offering on June 29, 2015 generating gross proceeds of $20 million at $5 per share!.
2. Strengthened senior leadership team with key appointments: William J. Sandborn, M.D. to Medical Advisory Board AnnKatrin Petersen-Jappelli, M.D., M.SC. as Chief Medical Officer
3. Retained William M. Merino as Senior Clinical and Regulatory Advisor

the most important update was the confirmation of data release:" upcoming Phase 2b/3 clinical trial of RP-G28, the potentially first FDA-approved therapy for lactose intolerance, in early 2016".

A very solid balance sheet. Rare assets/debt ratio of 16 and trading under Cash.i can't find another bio company on so great balance sheet,debt is so tiny($1.1m) and total assets(including Cash), are 16 times total liabilities.

RP-G28, a first-in-class treatment for lactose intolerance suffered by >1 billion worldwide.the company mentioned that "we know of no other drug candidates in advanced clinical trials for treating lactose intolerance",think of the market potential.

Their Patents covering methods of using RP-G28 will be expired on 2030,and they also own pending applications in the United State and Europe covering RP-G28 analogs.

so far the results were primed for my understanding and they recently closed a public offering of 4,000,000 shares of the Company’s common stock at an initial public offering price of $5.00 per share.

Bakers Bros. banking on her. they reported only 8 new positions (Q2).one of them was RTTR (a stake of 400,000 shares),so i believe something good is brewing here.
Bakers Bros, for sure did their DD prior to this investment.also closed public offering of $20 million at $5 per share.There is NO WAY in Hell they would plop down $20 at $5 per share on the treatment for lactose intolerance unless their people did their DD and went over the data. They had to see some very encouraging data they were impressed with.they're gonna want to see at least the $7 price per share to make it worth their while,and there is no way they gonna sell under Purchase price, when they will be able to do that imo.

just got a $7 PT by Aegis.

Institutional Holdings increased dramatically.Actually from alnost a zero ownership a year ago to about 20% ownership a/o today.also zero sells past 12 months http://www.nasdaq.com/symbol/rttr/ownership-summary

3 filings dated Oct 2015 all Insiders purchases ( code A).
http://www.otcmarkets.com/stock/RTTR/filings

"We are committed to developing cutting-edge treatments for gastrointestinal diseases. Our management team, with years of relevant clinical, regulatory and commercial experience, is supported by an outstanding medical advisory board comprised of foremost researchers in lactose intolerance and gastrointestinal diseases".
http://www.ritterpharmaceuticals.com/leadership/overview